January 2016 Edition Vol.11, Issue 1

Phase 3 Hits and Misses of 2015

Phase 3 Hits and Misses of 2015 (continued)

2015 was a banner year for FDA approvals, and there was no shortage of cancer therapies included in the list — oncology was at the top of the leader board as the therapeutic category winning the most new drug approvals this past year. 

Among the cancer therapies that U.S. regulators greenlighted were the first approved U.S. biosimilar, the first oncolytic virus therapy, several new multiple myeloma drugs, and new indications for the immunotherapies Opdivo and Keytruda in lung (both drugs) and kidney cancer (Opdivo only). 

See our table below:

Pages: 1 2 3

Post a Comment

OBR Archives

To view previous issues of OBR green you can visit our archives. The entire library of OBR green articles is searchable.